<DOC>
	<DOC>NCT01470053</DOC>
	<brief_summary>The purpose of this study is to evaluate of efficacy and safety of mometasone furoate plus azelastine HCl in patients with perennial allergic rhinitis.</brief_summary>
	<brief_title>Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Patients over 12 years of age Medical history of perennial allergic rhinitis for at least two years Moderate ro severe nasal symptom (during placebo runin period AM rTNSS or PM rTNSS≥8) Positive skin prick test result within the previous 12 months patients with active asthma that required therapy with inhaled or oral corticosteroids or longterm βagonist patients with severe rhinostenosis, severely deviated nasal septum or local infection on the nasal mucous membrane patients with herpes zoster, glaucoma or cataract patients with history of operation or damage on nasal cavity or ocular region patients with druginduced rhinitis patients with history of respiratory infection which requires antibiotic therapy within the previous 14 days Patients with lung disease including COPD Patients with history of immunotherapy or ongoing immunotherapy patients administered with super potent or potent corticosteroid patients administered with intramuscular or intraarticular steroid within the previous 3 months patients administered with subcutaneous omalizumab within the previous 5 months</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>mometasone furoate</keyword>
	<keyword>azelastine HCl</keyword>
	<keyword>perennial allergic rhinitis</keyword>
</DOC>